genOway offers highly predictive preclinical models and solutions to bridge the gap between preclinical research and clinical success.
The company has developed a comprehensive, high-quality portfolio of humanized mouse models that closely reflect human biology. These models are used to evaluate immunotherapies, typically in cancer, inflammation, and autoimmune diseases; via an offering that helps accelerate the transition of novel compounds from preclinical to clinical studies.
Headquartered in Lyon, France, genOway operates in more than 28 countries in America, Europe and Asia. genOway’s clients include 380 institutions, including the world's most prestigious academic research laboratories, CROs and 170 life sciences companies, including 17 top global 20 pharmaceutical companies.